Implementation of Hospital Policy for Healthcare Workers and Patients Exposed to Varicella-Zoster Virus

Si-Hyun Kim,1,2,3 Sun Hee Park,1,2,3 Su-Mi Choi,1,2 and Dong-Gun Lee1,2,4

1Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
4Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

ABSTRACT

Varicella-zoster virus (VZV) causes a highly contagious and generally benign, self-limited disease. However, in high-risk populations including immunocompromised patients, pregnant women, and neonates, VZV infection can be associated with significant morbidity and mortality. Healthcare-associated transmission of VZV occurs among healthcare workers (HCWs) and patients by airborne transmission or by direct contact with the index case. To minimize the risk of transmission in healthcare settings, all VZV-susceptible HCWs should be encouraged strongly to be immunized with the varicella vaccine. For post-exposure management, active immunization (varicella vaccine), passive immunization (varicella-zoster immune globulin) and/or antiviral agents, and isolation could be used in specific situations. To prevent the transmission of VZV infection in the hospital settings, the development and implementation of hospital policies for appropriate infection control is also warranted. This article reviews the general information and healthcare-associated transmission of VZV and summarizes the recommendations for the pre- and post-exposure management of HCWs and patients, in hospital settings.

Keywords: Varicella-Zoster Virus Infection; Occupational Exposure; Vaccination; Immune Globulin; Hospitals, Isolation

INTRODUCTION

Varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the family Herpesviridae, causes one of the most communicable diseases in humans.1,2 There are two distinct clinical diseases caused by VZV: varicella (or chickenpox) which is caused by the primary VZV infection as well as herpes zoster (or shingles), caused by the endogenous reactivation of the latent infection.2,3 Although VZV infection is generally a benign, self-limited illness in immunocompetent children, serious and life-threatening complications occur more commonly in certain groups of patients, particularly neonates, pregnant women, adults, and immunocompromised persons.4,5 For these reasons, infection control of VZV is important in hospital settings where patients are at higher risk of severe morbidity and mortality. In addition to patients, healthcare workers (HCWs) have the potential of exposure to VZV from infected patients. Furthermore, VZV can be transmitted to and from HCWs and other susceptible patients in the hospitals. To prevent the transmission of VZV infection in the
hospital settings, the development and implementation of hospital policies for appropriate infection control is warranted. This article focuses on the healthcare-associated transmission of VZV, the infection control measures in the hospital settings, and summarizes the key points of the recommendations on the management of patients and HCWs exposed to VZV.

**Epidemiology and Clinical Manifestations**

Primary VZV infection causes varicella (also known as chickenpox), which typically occurs during childhood. After the primary infection, VZV characteristically establishes lifelong latency in the dorsal root or cranial nerve ganglia. Reactivation of the latent virus can occur years or decades later, resulting in herpes zoster, commonly called shingles.

**Varicella**

Varicella is endemic worldwide, occurring mainly in children, and affects persons of both sexes and all races equally. Although the disease occurs throughout the year in temperate climates, it has a seasonal variation, with peak incidence during late winter and early spring. The epidemiology of varicella has changed dramatically with the implementation of the childhood varicella vaccination program. In many countries including the United States of America (USA), Germany, Australia, Greece, and Saudi Arabia, the incidence of varicella has declined following the National Immunization Program (NIP) implementation for varicella vaccine; and vaccinated persons presents with milder disease. In Korea, a live attenuated varicella vaccine was first introduced in 1988 and the NIP recommended a universal one-dose varicella vaccination for children aged 12 to 15 months since 2005. Seroprevalence, in subjects aged 1 to 79 years, determined via enzyme-linked immunosorbent assay, is about 90% in Korea. However, seroprevalence increased with age from 67% in those aged 1 to 4 years to > 98% in subjects aged over 20 years. However, the decline in incidence of varicella reported in other countries has not yet been shown by the National Notifiable Disease Surveillance System in Korea; rather, it seems to have been increasing over time. In the Korea Centers for Diseases Control and Prevention Infectious Diseases Surveillance Report, varicella has continued to increase from 22 cases per 100,000 population in 2006 to 155 cases per 100,000 population in 2017. This increase could have resulted from a number of factors including a change in the disease reporting rate due to improvement in diagnostics and surveillance, vaccine effectiveness, and waning of immunity after the only one-dose vaccination; thus, further investigation is warranted to elucidate these factors.

Varicella is characterized by a generalized pruritic rash that begins to appear on the face and trunk, then, rapidly spread to the extremities and other areas of the body. A prodrome of low-grade fever, headache, malaise, and flu-like symptoms may occur 1 to 2 days before the onset of exanthem. The skin lesions, the hallmark of varicella, are usually pruritic, and evolve from maculopapules to vesicles, pustules, and eventually scabs, over hours to days. As a result, the lesions, at all stages of evolution are found early in the disease. Most blisters would have fully crusted within one week of the onset of infection.

The severity of disease varies in certain population groups. Approximately 15%–20% of one-dose vaccinated persons may develop varicella if exposed to VZV. When varicella develops in vaccinated persons, the symptoms are often mild, with little or no fever. The skin lesions are fewer in number and atypical in nature, predominantly maculopapular rather than vesicular in this population. In contrast, immunocompromised patients have more numerous skin lesions,
often with hemorrhagic base, and take nearly three times longer to heal. Complications occur more commonly in the following high-risk groups: neonates, adolescents, adults, pregnant women, and immunocompromised persons (including transplant recipients, patients with human immunodeficiency virus [HIV] or cancer, and patients on anti-cancer chemotherapy, immunosuppressive medications, or long-term use of steroids). Consequently, varicella in these patients causes significant morbidity and mortality. Varicella during pregnancy affects both the mother and the fetus or newborn. Maternal varicella is associated with increased risk of varicella pneumonia, which can be life threatening. If a pregnant woman has varicella during the early gestational period, the fetus is at risk of congenital varicella syndrome. Newborns who have varicella within 2 weeks of delivery from peripartum exposure or from acquisition in healthcare facilities have the highest risk of neonatal varicella. The mortality rate of neonatal varicella is up to 30%.

**Herpes zoster**

Herpes zoster is a sporadic disease that occurs in persons who are seropositive for VZV. The mechanisms of latency and reactivation of VZV are not well known. A decline in the level of T-cell immunity to VZV presumably correlates with the reactivation of latent VZV, resulting in herpes zoster. The most important risk factor for herpes zoster is increasing age. Herpes zoster affects about 20% or more of the population overall, but the incidence rates progressively increase with age, particularly after 50 years of age. Patients with medical conditions or medications that suppress the immune system also have an increased risk of herpes zoster, including patients with HIV, cancer, or autoimmune disease, transplant recipients, and patients on anti-cancer chemotherapy, immunosuppressive medications, or steroids. Some studies found that herpes zoster occurred more in women than in men and less in Blacks than Whites. Recurrence of disease is uncommon, but immunocompromised patients can experience a second and even third episode of herpes zoster. The incidence rates of herpes zoster have shown a gradual increase over a long period of time in the United States. This trend is similarly observed in Korea. The annual number of clinical visits due to herpes zoster in Korea was reported to have increased from 7.93 cases per 1,000 population in 2003 to 12.54 cases per 1,000 population in 2007. The reason for this increase remains unknown. Some experts are concerned that mandatory childhood varicella vaccination could have led to the increase in herpes zoster incidence. However, there are currently no data available to support this. The disease burden of herpes zoster in Korea is considerably higher than that reported for other countries. The reason for this difference is not clear and further studies are needed. There are two types of vaccines licensed for the prevention of herpes zoster in the USA: Zoster Vaccine Live (live attenuated vaccine containing the Oka VZV strain with at least 14 times the potency of varicella vaccine) and Recombinant Zoster Vaccine (adjuvanted, recombinant subunit vaccine containing VZV glycoprotein E). In Korea, only Zoster Vaccine Live has been available since 2013. Zoster Vaccine Live is contraindicated in immunocompromised patients especially in transplant recipients because of the potential risk of disseminated VZV infection.

The typical clinical manifestation of herpes zoster includes painful and unilateral vesicular eruption, with a dermatomal distribution. Generally, pain precedes the erythematous maculopapular rash by 48 to 72 hours, then, the skin lesions rapidly evolve into vesicles or bullae. Although the lesions crust within 7 to 10 days in immunocompetent patients, it could take longer to heal in immunocompromised patients. Postherpetic neuralgia, the most common complications of herpes zoster, may occur in up to 50% of patients older than 50 years and can persist for more than 1 month after the skin lesions resolves. Occasionally, herpes zoster can become disseminated, with > 20 skin lesions beyond the primary and adjacent dermatomes or
with visceral involvements.\textsuperscript{28,56} Like varicella, herpes zoster in immunocompromised patients is more severe, and the risk of complications and developing disseminated zoster is higher.\textsuperscript{30,43,57,58}

**TRANSMISSION IN HEALTHCARE SETTINGS**

VZV is highly contagious and the disease is more severe in immunocompromised patients. That is why transmission of VZV in hospitals, where potentially susceptible immunocompromised patients are housed, is a serious problem. The risk of transmission is highest in pediatric patients, and seronegative adult patients and HCWs are also at high risk for acquisition.\textsuperscript{59,60} Transmission of VZV to previously vaccinated persons (breakthrough varicella) can occur.\textsuperscript{61,62} A patient with either varicella or herpes zoster can be a source of transmission in healthcare settings.\textsuperscript{63-69} The incubation period of VZV is generally 14 to 16 days, with a range of 10 to 21 days after exposure to the characteristic rash.\textsuperscript{3} Secondary attack rates of varicella among susceptible persons within a household are between 70\% and 90\%.\textsuperscript{15,70} There are no available data concerning the attack rate of varicella in hospital settings. Although herpes zoster is less contagious than varicella, it may however be a more frequent cause of healthcare-associated infection.\textsuperscript{67,68}

Transmission of VZV in hospital settings can occur via airborne route or through contact with contaminated environment or hands of HCWs. Healthcare-associated transmission from an index case with either varicella or disseminated zoster to susceptible patients or HCWs appears to be primarily through the airborne route. The virus spreads by droplets and aerosols from the nasopharynx 1 to 2 days before the onset of rash and from vesicular lesions containing large amount of virus particles. Patients with either varicella or disseminated zoster are regarded as being infectious, 48 hours before the onset of rash until all vesicles are crusted. Susceptible hosts may also acquire the virus by direct or indirect contacts with skin lesions of patients with either varicella or herpes zoster. Although rare, there have been reports of airborne transmission of VZV in hospital settings from patients with herpes zoster.\textsuperscript{69,71,72} Some studies reported that aerosolized VZV DNA is rapidly and widely spread to the environment even from patients with herpes zoster.\textsuperscript{69,73}

**PREVENTION AND CONTROL OF HEALTHCARE-ASSOCIATED EXPOSURES**

In healthcare facilities, both HCWs and patients should be evaluated to determine the appropriate management approach for prevention and infection control of VZV infections. The major measures of infection control include isolation, varicella vaccine, varicella-zoster immune globulin (VZIG) or intravenous immune globulin (IVIG), and antiviral agents.\textsuperscript{11,74-77} Definitions of key terms are summarized in Table 1.

**Pre-exposure management of HCWs**

HCWs with incubating or clinical varicella are significant sources of exposure to primary VZV infection in healthcare facilities. On the other hand, HCWs are at risk of acquisition of VZV infection from patients who have varicella or herpes zoster. Therefore, the first step in the prevention of healthcare-associated transmission of VZV is to minimize the number of susceptible HCWs.\textsuperscript{78} The history of prior varicella or vaccination should be determined at the time of initial employment in all HCWs. The seroprevalence of varicella among HCWs born
Serologic screening, such as VZV immunoglobulin G (IgG), before vaccination is indicated for persons with no or uncertain history of varicella. All HCWs without evidence of immunity to VZV should receive two-doses of varicella vaccine, 4 to 8 weeks apart, unless they are contraindicated. Evidence of immunity for HCWs includes one of the followings: 1) written documentation with two-doses of vaccine, 2) laboratory evidence of immunity or laboratory confirmation of disease, 3) diagnosis or verification of history of varicella or herpes zoster by a healthcare provider. However, routine serologic testing after vaccination is not recommended.

Table 2 shows the contraindications for varicella vaccination.

Management of HCWs exposed to VZV
For all exposures, the potential of VZV acquisition should be assessed as soon as feasible. HCWs with evidence of immunity can be allowed to continue working and should be monitored daily for symptoms or signs of varicella, within 8 to 21 days of exposure. All susceptible HCWs exposed to VZV should be screened to assess their immunity to VZV. HCWs without evidence of immunity should receive two-doses of varicella vaccine within 3 to 5 days of exposure, if there are no contraindications to varicella vaccination. If HCWs who have received only one dose of varicella vaccine are exposed to VZV, the second dose of vaccine is recommended within 3 to 5 days after exposure, at least 4 weeks after the first dose. Seronegative HCWs who are immunocompromised or pregnant should be considered for VZIG as soon as possible within 10 days of exposure. Furthermore, seronegative HCWs should be considered for reassignment to low-risk areas or be placed on administrative leave from day 8 to day 21 of the exposure. VZIG may prolong the incubation period by one week, thus HCWs who receive VZIG should be excluded from work from

| Term                              | Definition                                                                 |
|-----------------------------------|---------------------------------------------------------------------------|
| Exposure                          | - Varicella or disseminated zoster: face-to-face contact for at least 5 minutes, or contact in the same room for at least 1 hour* |
|                                   | - Herpes zoster: intimate contact, for example touching or hugging; or direct contact to open cutaneous lesions          |
| Newborns                          | When a mother has varicella 5 days before to 2 days after delivery        |
| HCWs                              | Workers who have direct contact with patients (including both clinical and non-clinical HCWs) |
| Incubation period                 | Usually 10 to 21 days                                                    |
| Index case                        | The first person with VZV infection identified in a chain of transmission |
| Period of infectivity             | - Varicella: from 48 hours prior to the onset of the exanthem until all lesions are crusted     |
|                                   | - Herpes zoster: from the appearance of vesicles until all lesions are crusted |
| Susceptible to VZV                | At risk of developing VZV infection because of no antibodies to VZV (usually no history of both varicella and vaccination) |

HCW = healthcare worker, VZV = varicella-zoster virus.

*The contact should be non-transient. Experts differ in the opinion about the duration of contact; some suggest 5 minutes and others up to 1 hour.

Table 1. Definitions of key terms

Table 2. Contraindications to varicella vaccination

Severe allergic reaction (such as anaphylaxis) after a previous dose of varicella vaccine or to any component of varicella vaccine
Pregnancy or possibility of pregnancy within 1 month
Severe immunosuppression
- Solid tumors and hematologic malignancies
- Current receipt of anti-cancer chemotherapy
- Primary or acquired immunodeficiency
- Immunosuppressive agents administered to patients who have undergone solid organ or hematopoietic stem cell transplant
- Biologic agents for autoimmune conditions
- HIV infection with CD4 cell count < 200 cells/mm³
- Long-term high-dose systemic corticosteroids (prednisone ≥ 20 mg/day or 2 mg/kg/day or its equivalent for 14 days or more)

Active, untreated tuberculosis
Current febrile illness

HIV = human immunodeficiency virus.

in Korea before 1988 is reported as 96%. Serologic screening, such as VZV immunoglobulin G (IgG), before vaccination is indicated for persons with no or uncertain history of varicella. All HCWs without evidence of immunity to VZV should receive two-doses of varicella vaccine, 4 to 8 weeks apart, unless they are contraindicated. Evidence of immunity for HCWs includes one of the followings: 1) written documentation with two-doses of vaccine, 2) laboratory evidence of immunity or laboratory confirmation of disease, 3) diagnosis or verification of history of varicella or herpes zoster by a healthcare provider. However, routine serologic testing after vaccination is not recommended.

Table 2 shows the contraindications for varicella vaccination.
day 8 to day 28 of the exposure. If VZV infection is suspected, the HCWs must be excluded from work immediately. Suggested algorithm for the evaluation and management after exposure to VZV in healthcare settings is shown in Fig. 1.

**Table 3. Indications for VZIG after an exposure to VZV**

| Indications for VZIG after an exposure to VZV |
|-----------------------------------------------|
| Immunocompromised patients without evidence of immunity to VZV |
| Pregnant women without evidence of immunity to VZV |
| Newborn infants whose mothers had signs and/or symptoms of varicella 5 days before to 2 days after delivery |
| Hospitalized premature infants (≥ 28 weeks of gestation) whose mother had no evidence of immunity to VZV |
| Hospitalized premature infants (< 28 weeks of gestation or ≤ 1,000 g birth weight), regardless of maternal immunity |

VZIG = varicella-zoster immune globulin, VZV = varicella-zoster virus.

**Fig. 1.** Suggested algorithm for the evaluation and management after exposure to VZV in healthcare settings. VZV = varicella-zoster virus, IVIG = intravenous immune globulin, VZIG = varicella-zoster immune globulin.

*For immunocompromised patients, a 7-day course of acyclovir or valacyclovir may be considered if both VZIG and IVIG are not available.
Management of patients exposed to VZV

First, the immunologic status of all patients exposed to VZV should be assessed. Susceptible patients who are exposed to VZV should be placed on airborne and contact precautions from day 8 to day 21 of the exposure. If VZIG or IVIG is administered, these precautions should be maintained until day 28 of the exposure.90

Immunocompetent patients

The principle of management in immunocompetent patients is the same as in HCWs. In general, immunocompetent patients who have immunity to VZV need no further follow-up. All susceptible immunocompetent patients, who are 12 months of age or older, may be candidates for varicella vaccination. Varicella vaccine should be administered as soon as possible, preferably within 3 to 5 days after exposure.

All exposed patients without evidence of immunity should be discharged as soon as possible.28,59,83 If a susceptible patient could not be discharged, the patient should be placed in isolation until day 21 of the exposure.

Immunocompromised patients

Serologic testing should be performed in all immunocompromised patients as soon as possible. Patients without evidence of immunity to VZV and who are at high risk of complications should be administered with VZIG (Table 2).28,83,88,91 Some experts also recommend VZIG as postexposure prophylaxis for highly immunocompromised patients, such as hematopoietic stem cell transplant recipients, regardless of serologic test results. This is because the sensitivity and specificity of serologic tests are unavailable and VZV IgG may not be protective in these patients. Intramuscular administration of VZIG (1 vial [125 units] per 10 kg body weight; maximum of 5 vials) is recommended as soon as possible within 10 days.89 If VZIG is not available, IVIG (≥ 400 mg/kg) can be an alternative.28,75 A 7-day course of acyclovir (800 mg 5 times daily) or valacyclovir (1 g 3 times daily), beginning 7 to 10 days after exposure may be considered as chemoprophylaxis for immunocompromised patients if both VZIG and IVIG are not available.28 However, there are no studies on postexposure chemoprophylaxis for immunocompromised patients. All susceptible patients should be placed in isolation until day 21 of exposure. In patients who receive VZIG, isolation should be continued until day 28 of exposure.

Pregnant women

Varicella vaccine is contraindicated in pregnant women and VZIG is recommended in all susceptible pregnant women exposed to VZV as soon as possible, within 10 days.11,12,28,88,89,92 The use of VZIG could reduce both the severity of maternal disease and the risk of fetal infection. There are no studies on whether the use of acyclovir is effective in the prevention of varicella in pregnant women after exposure to VZV. Because maternal varicella infection complicated with pneumonia is a medical emergency, careful follow-up for signs of active disease despite passive immunization is needed. If maternal disease occurs despite VZIG, patients should be treated with antiviral agents. Susceptible pregnant women who do not develop varicella should receive varicella vaccine after delivery.11,12

Neonates

Newborns may be infected with VZV by peripartum maternal infection or by postnatal exposure. Routine screening for maternal immunity to VZV is recommended during early pregnancy.11,12 If the maternal immune status is not known, the mother should have a
serologic testing for VZV as soon as possible. Because varicella vaccine has been approved for children aged 12 months through 12 years, VZIG is recommended to prevent varicella and ameliorate the disease course in neonates. Indications for VZIG in newborns with significant exposure to VZV are shown in Table 2. If VZIG is unavailable, IVIG or chemoprophylaxis with acyclovir could be considered.

Infants whose mother has active varicella within 21 days prior to delivery should be isolated from other infants. If a mother has symptoms of varicella within 5 days before or 2 days after delivery, the infant should be isolated from the mother until she is no longer infectious.

**TREATMENT OF CONFIRMED OR SUSPECTED INFECTION**

**Work restriction and isolation precautions**

All HCWs who develop varicella or disseminated zoster should be excluded from work until all lesions are crusted. Although immunocompetent hosts with dermatomal herpes zoster with covered lesions may continue to work, advice for reassignment to low-risk patients should be offered, until all lesions are crusted.

Unvaccinated susceptible HCWs should avoid contact with patients who have confirmed or suspected varicella or herpes zoster. All patients with varicella or disseminated zoster should be placed on airborne and contact precautions until all lesions are crusted. For immunocompetent patients with dermatomal herpes zoster, standard precautions and complete covering of the skin lesions are recommended.

**Antiviral therapy**

HCWs and patients who develop clinical symptoms despite active or passive immunization should be appropriately treated with antiviral therapy. Antiviral therapy can shorten the duration of disease, reduce the total number of new lesions, accelerate cutaneous healing, and reduce acute neuritis. Acyclovir is approved for the treatment of both varicella and herpes zoster, and both oral (800 mg 5 times daily for 7 to 10 days) and intravenous (10 mg/kg every 8 hours for 7 to 10 days) forms are available. Oral valacyclovir (1 g 3 times daily for 7 to 10 days) and famciclovir (250 to 500 mg 3 times daily for 7 to 10 days), the prodrugs of acyclovir and penciclovir, have been licensed for the treatment of herpes zoster.

**CONCLUSION**

Despite implementation of routine childhood varicella vaccination NIP program in Korea, varicella and herpes zoster continue to occur. VZV is highly contagious and can cause serious complications in high-risk populations. Healthcare-associated transmission of VZV is also well documented from both varicella and herpes zoster. The prevention and control of VZV infection in hospital settings is important for both HCWs and in-hospital patients. All HCWs should be screened for immunity to VZV at the time of initial employment, then varicella vaccines are recommended to all seronegative HCWs, if there are no contraindications to vaccine use. Susceptible HCWs and patients exposed to VZV should be isolated from other members of staff or patients, appropriately. Active immunization should be performed when it is safe, and passive immunization can be considered, based on specific indications.
REFERENCES

1. Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella zoster virus infection. *Nat Rev Dis Primers* 2015;1:15016.
2. Whitley RJ. Chickenpox and herpes zoster. In: Bennett JE, Dolin R, Blaser MJ, editors. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 8th ed. Philadelphia, PA: Elsevier Incorporated; 2015, 1731-7.
3. Heininger U, Seward JF. Varicella. *Lancet* 2006;368(9544):1365-76.
4. Arvin AM. Varicella-zoster virus. *Clin Microbiol Rev* 1996;9(3):361-81.
5. Marin M, Watson TL, Chaves SS, Civen R, Watson BM, Zhang JX, et al. Varicella among adults: data from an active surveillance project, 1995–2005. *J Infect Dis* 2008;197 Suppl 2:S94-100.
6. Brunell PA. Fetal and neonatal varicella-zoster infections. *Semin Perinatol* 1983;7(1):47-56.
7. Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S. Life-threatening complications of varicella. *Am J Dis Child* 1981;135(10):896-9.
8. Jaeggi A, Zurbruegg RP, Aebi C. Complications of varicella in a defined central European population. *Arch Dis Child* 1998;79(6):472-7.
9. Bonhoeffer J, Baer G, Muehleisen B, Aebi C, Nadal D, Schaad UB, et al. Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. *Eur J Pediatr* 2005;164(6):366-70.
10. Preblud SR. Varicella: complications and costs. *Pediatrics* 1986;78(4 Pt 2):728-35.
11. Shrim A, Koren G, Yudin MH, Farine D, Gagnon R, Hudon L, et al. Management of varicella infection (chickenpox) in pregnancy. *J Obstet Gynaecol Can* 2012;34(3):287-92.
12. Gardella C, Brown ZA. Managing varicella zoster infection in pregnancy. *Cleve Clin J Med* 2007;74(4):290-6.
13. Gershon AA, Chen J, Davis L, Krinsky C, Cowles R, Reichard R, et al. Latency of varicella zoster virus in dorsal root, cranial, and enteric ganglia in vaccinated children. *Trans Am Clin Climatol Assoc* 2012;123:17-33.
14. Galetta KM, Gilden D. Zeroing in on zoster: a tale of many disorders produced by one virus. *J Neurol Sci* 2015;358(1-2):38-45.
15. Straus SE, Ostrove JM, Inchauspé G, Felser JM, Freifeld A, Croen KD, et al. NIH conference. Varicella-zoster virus infections, Biology, natural history, treatment, and prevention. *Ann Intern Med* 1988;108(2):221-37.
16. Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. *Vaccine* 1991;9(9):643-7.
17. Reuss AM, Feig M, Kappelmayer L, Siedler A, Eckmanns T, Poggensee G. Varicella vaccination coverage of children under two years of age in Germany. *BMC Public Health* 2010;10(1):502.
18. Fu C, Wang M, Liang J, Xu J, Wang C, Bialek S. The effectiveness of varicella vaccine in China. *Pediatr Infect Dis J* 2010;29(8):690-3.
19. Marshall HS, McIntyre P, Richmond P, Bretty JP, Royle JA, Gold MS, et al. Changes in patterns of hospitalized children with varicella and of associated varicella genotypes after introduction of varicella vaccine in Australia. *Pediatr Infect Dis J* 2013;32(5):530-7.
20. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. *JAMA* 2005;294(7):797-802.
21. Perella D, Wang C, Given R, Viner K, Kuguru K, Daskalaki I, et al. Varicella vaccine effectiveness in preventing community transmission in the 2-dose era. *Pediatrics* 2016;137(4):e20152802.
PUBMED | CROSSREF

22. Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, et al. Varicella vaccination in Japan, South Korea, and Europe. *J Infect Dis* 2008;197 Suppl 2:S185-90.
PUBMED | CROSSREF

23. Korea Centers for Disease Control and Prevention. National Immunization Program guide. https://nip.cdc.go.kr/irgd/index.html. Accessed June 30, 2018.

24. Lee H, Cho HK, Kim KH. Seroepidemiology of varicella-zoster virus in Korea. *J Korean Med Sci* 2013;28(2):195-9.
PUBMED | CROSSREF

25. Korea Centers for Disease Control and Prevention. Infectious diseases portal. http://www.cdc.go.kr/npt/biz/npp/ist/bass/bassDissStatsMain.do. Updated 2018. Accessed June 30, 2018.

26. Chaves SS, Zhang J, Given R, Watson BM, Carbajal T, Perella D, et al. Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005. *J Infect Dis* 2008;197 Suppl 2:S127-31.
PUBMED | CROSSREF

27. Lamont RF, Sobel JD, Carrington D, Mazaki-Tovi S, Kusanovic JP, Vaisbuch E, et al. Varicella-zoster virus (chickenpox) infection in pregnancy. *BJOG* 2011;118(10):1155-62.
PUBMED | CROSSREF

28. Kimberlin DW, Brady MT, Jackson MA, Long SS. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Itasca, IL: American Academy of Pediatrics; 2018.

29. Tunbridge AI, Breuer J, Jeffery KJ. British Infection Society. Chickenpox in adults - clinical management. *J Infect* 2008;57(2):95-102.
PUBMED | CROSSREF

30. Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. *J Infect Dis* 2002;186 Suppl 1:S91-8.
PUBMED | CROSSREF

31. Bielas KM, Swamy GK, Permar SR. Perinatal cytomegalovirus and varicella zoster virus infections: epidemiology, prevention, and treatment. *Clin Perinatol* 2015;42(1):61-75.
PUBMED | CROSSREF

32. Smith CK, Arvin AM. Varicella in the fetus and newborn. *Semin Fetal Neonatal Med* 2009;14(4):209-47.
PUBMED | CROSSREF

33. Benoit G, Etchemendigaray C, Nguyen-Xuan HT, Vauloup-Fellous C, Ayoubi JM, Picone O. Management of varicella-zoster virus primary infection during pregnancy: a national survey of practice. *J Clin Virol* 2015;72:4-10.
PUBMED | CROSSREF

34. Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Seroprevalence of varicella-zoster virus in Korea. *J Med Virol* 2010;82(12):2123-6.
PUBMED | CROSSREF

35. Kim YI, Lee CN, Lim CJ, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. *J Korean Med Sci* 2014;29(12):1706-10.
PUBMED | CROSSREF

36. Cohen JJ. Clinical practice: herpes zoster. *N Engl J Med* 2013;369(3):255-63.
PUBMED | CROSSREF

37. Schmader K. Herpes zoster in older adults. *Clin Infect Dis* 2001;32(10):1481-6.
PUBMED | CROSSREF

38. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. *Bmj* 2014;348:g2911.
PUBMED | CROSSREF

39. Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. *J Heart Lung Transplant* 2008;27(1):11-6.
PUBMED | CROSSREF

40. Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. *Transpl Infect Dis* 2008;10(4):260-8.
PUBMED | CROSSREF

41. Smitten AL, Choi HK, Hochberg MC, Sussa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. *Arthritis Rheum* 2007;57(8):1431-8.
PUBMED | CROSSREF
42. Grabar S, Tattevin P, Selinger-Leneman H, de La Blanchardiere A, de Truchis P, Rabaud C, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis 2015;60(8):1269-77.

43. Rogers SY, Irving W, Harris A, Russell NH. Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant 1995;15(5):805-7.

44. Cho SY, Lee HJ, Lee DG. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea. Korean J Intern Med 2018;33(2):256-76.

45. Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. J Infect Dis 1995;171(3):701-4.

46. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011;86(2):88-93.

47. Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012;206(2):190-6.

48. Rimland D, Moanna A. Increasing incidence of herpes zoster among Veterans. Clin Infect Dis 2010;50(7):1000-5.

49. Cho WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Disease burden of herpes zoster in Korea. J Clin Virol 2010;47(4):325-9.

50. Whitley RJ. Changing dynamics of varicella-zoster virus infections in the 21st century: the impact of vaccination. J Infect Dis 2005;191(12):1999-2001.

51. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis 2008;197 Suppl 2:S224-7.

52. Song H, Lee J, Lee M, Choi WS, Choi JH, Lee MS, et al. Burden of illness, quality of life, and healthcare utilization among patients with herpes zoster in South Korea: a prospective clinical-epidemiological study. Int J Infect Dis 2014;20:23-30.

53. Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc 2015;90(7):865-73.

54. Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc 2015;90(7):865-73.

55. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med 2014;371(16):1526-33.

56. Whitley RJ, Gnann JW Jr, Hinthorn D, Liu C, Pollard RB, Hayden F, et al. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. J Infect Dis 1992;165(3):450-5.

57. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995;21(2):370-5.

58. Rusthoven JJ, Ahlgren P, Elhakim T, Pinfold P, Reid J, Stewart L, et al. Varicella-zoster infection in adult cancer patients. A population study. Arch Intern Med 1988;148(7):1501-6.

59. Palmore TN, Henderson DK. Nosocomial herpesvirus infections. In: Bennett JE, Dolin R, Blaser MI, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier Incorporated; 2015, 3377-80.
60. Apisarnthanarak A, Kitphati R, Tawatsupha P, Thongphubeth K, Apisarnthanarak P, Mundy LM. Outbreak of varicella-zoster virus infection among Thai healthcare workers. *Infect Control Hosp Epidemiol* 2007;28(4):430-4.

61. Park CS, Kim DS, Kim KH. Varicella outbreak in the patients during group therapy: seroprevalence in a healthcare system during breakthrough varicella occurrence. *Clin Exp Vaccine Res* 2013;2(2):140-3.

62. Adler AL, Casper C, Boeckh M, Heath J, Zerr DM. An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients. *Infect Control Hosp Epidemiol* 2008;29(9):866-70.

63. Weber DJ, Rutala WA, Hamilton H. Prevention and control of varicella-zoster infections in healthcare facilities. *Infect Control Hosp Epidemiol* 1996;17(10):694-705.

64. Saidel-Odes L, Borer A, Riesenberg K, Frenkel A, Sherlis R, Bouhnick L, et al. An outbreak of varicella in staff nurses exposed to a patient with localized herpes zoster. *Scand J Infect Dis* 2010;42(8):620-2.

65. Leclair JM, Zaia JA, Levin MJ, Congdon RG, Goldmann DA. Airborne transmission of chickenpox in a hospital. *N Engl J Med* 1980;302(8):450-3.

66. Bloch KC, Johnson JG. Varicella zoster virus transmission in the vaccine era: unmasking the role of herpes zoster. *J Infect Dis* 2012;205(9):1331-3.

67. Cholongitas E, Ilonidis G. Transmission of varicella-zoster virus originating from a patient with localized herpes zoster: Implications for infection control? *Am J Infect Control* 2010;38(8):669-70.

68. Wreghitt TG, Whipp J, Redpath C, Hollingworth W. An analysis of infection control of varicella-zoster virus infections in Addenbrooke’s Hospital Cambridge over a 5-year period, 1987–92. *Epidemiol Infect* 1996;117(1):165-71.

69. Lopez AS, Burnett-Hartman A, Nambiar R, Ritz L, Owens P, Loparev VN, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. *J Infect Dis* 2008;197(5):646-53.

70. Wharton M. The epidemiology of varicella-zoster virus infections. *Infect Dis Clin North Am* 1996;10(3):571-81.

71. Breuer J. Herpes zoster: new insights provide an important wake-up call for management of nosocomial transmission. *J Infect Dis* 2008;197(5):635-7.

72. Johnson JA, Bloch KC, Dang BN. Varicella reinfection in a seropositive physician following occupational exposure to localized zoster. *Clin Infect Dis* 2011;52(7):907-9.

73. Yoshikawa T, Iiha M, Suzuki K, Suga S, Tomitaka A, Ueda H, et al. Rapid contamination of the environments with varicella-zoster virus DNA from a patient with herpes zoster, *J Med Virol* 2001;63(1):64-6.

74. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2008;57(RR-5):1-30.

75. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2007;56(RR-4):1-40.

76. Josephson A, Karanfil L, Gombert ME. Strategies for the management of varicella-susceptible healthcare workers after a known exposure. *Infect Control Hosp Epidemiol* 1990;11(6):309-13.

77. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. *Bone Marrow Transplant* 2009;44(8):453-558.
78. Weber DJ, Rutala WA. Occupational health update: focus on preventing the acquisition of infections with pre-exposure prophylaxis and postexposure prophylaxis. *Infect Dis Clin North Am* 2016;30(3):729-57.

79. Kang JH, Park YS, Park SY, Kim SB, Ko KP, Seo YH. Varicella seroprevalence among health care workers in Korea: validity of self-reported history and cost-effectiveness of prevaccination screening. *Am J Infect Control* 2014;42(8):885-7.

80. Nettleman MD, Schmid M. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers. *Infect Control Hosp Epidemiol* 1997;18(7):504-8.

81. Advisory Committee on Immunization PracticesCenters for Disease Control and Prevention (CDC). Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2011;60(RR-7):1-45.

82. O’Neill J, Buttery J. Varicella and paediatric staff: current practice and vaccine cost-effectiveness. *J Hosp Infect* 2003;53(2):117-9.

83. Salivury D, Ramsay M, Noakes K. *Immunisation against Infectious Diseases*. London: Stationery Office; 2006.

84. Breuer J. Monitoring virus strain variation following infection with VZV: is there a need and what are the implications of introducing the Oka vaccine? *Commun Dis Public Health* 2003;6(1):59-62.

85. Rubin LG, Levin MI, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014;58(3):e44-100.

86. Korea Centers for Disease Control and Prevention. *Epidemiology and Management of Vaccine Preventable Disease*. 5th ed. Cheongju, Korea: 2017.

87. Macartney K, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. *Cochrane Database Syst Rev* 2008;(3):CD001833.

88. Centers for Disease Control and Prevention (CDC), Updated recommendations for use of VariZIG--United States, 2013. *MMWR Morb Mortal Wkly Rep* 2013;62(28):574-6.

89. Centers for Disease Control and Prevention (CDC). FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. *MMWR Morb Mortal Wkly Rep* 2012;61(12):212.

90. Orenstein WA, Heymann DL, Ellis RJ, Rosenberg RL, Nakano J, Halsey NA, et al. Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin. *J Pediatr* 1981;98(3):368-73.

91. Lee DG. Vaccination of hematopoietic stem cell transplantation recipients: perspective in Korea. *Infect Chemother* 2013;45(3):272-82.

92. Rouse DJ, Gardner M, Allen SI, Goldberg RL. Management of the presumed susceptible varicella (chickenpox)-exposed gravida: a cost-effectiveness/cost-benefit analysis. *Obstet Gynecol* 1996;87(6):932-6.

93. Heuchan AM, Isaacs DAustralasian Subgroup in Paediatric Infectious Diseases of the Australasian Society for Infectious Diseases. The management of varicella-zoster virus exposure and infection in pregnancy and the newborn period. *Med J Aust* 2001;174(6):288-92.